Gemcitabine-induced supraventricular tachycardia

Oshrat E Tayer-Shifman¹, Yakir Rottenberg², and Mony Shuvy¹

¹Department of Medicine, and ²Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

ABSTRACT

The superior toxicity profile is one of the major reasons for the widespread use of gemcitabine in cancer treatment. Bone marrow suppression is the most common side effect, while non-hematological events are relatively infrequent. Cardiac toxicity is a rare complication and cardiac arrhythmia is even rarer. We report the case of a 67-year-old woman with metastatic breast cancer without a history of cardiac arrhythmia or ischemic heart disease who developed supraventricular tachycardia. The symptoms had started immediately after gemcitabine treatment. The arrhythmia responded poorly to common treatment and was eventually controlled by oral propranolol five days after admission. The present case suggests that supraventricular tachycardia may be triggered by gemcitabine even without underlying significant heart disease and may be resistant to conventional therapy.

Key words: gemcitabine, supraventricular tachycardia, adverse effect.

Correspondence to: Mony Shuvy, MD, Department of Medicine, Hadassah University Hospital, Ein Karem, PO Box 12000, Jerusalem 91120, Israel.
Tel +972-2-6776451; fax +972-2-6779993; e-mail monysh@gmail.com

Received June 20, 2008; accepted October 28, 2008.